Humacyte, Inc. (HUMA) reported a quarterly loss of $0.13 per share for the period ending December 2025, matching the Zacks Consensus Estimate but improving from a loss of $0.16 per share a year prior. The company posted revenues of $0.47 million, which fell short of expectations by 70.44%, compared to zero revenues last year. Over the past four quarters, Humacyte has surpassed consensus EPS estimates in two instances.
Year-to-date, Humacyte shares have declined approximately 19%, while the S&P 500 has dropped 5.4%. For the upcoming quarter, consensus EPS estimates stand at -$0.12 on projected revenues of $5.85 million, and for the current fiscal year, estimates are -$0.44 on revenues of $27.83 million.
Humacyte operates in the Medical – Biomedical and Genetics industry, which currently ranks in the bottom 40% of over 250 Zacks industries. The company maintains a Zacks Rank of #3 (Hold), indicating its stock is expected to perform in line with the market.
